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Abstract
 
Epidermal Langerhans cells (LCs) play a key role in immune defense mechanisms and in nu-
merous immunological disorders. In this report, we show that percutaneous infection of
 
C57BL/6 mice with the helminth parasite 
 
Schistosoma mansoni
 
 leads to the activation of LCs
but, surprisingly, to their retention in the epidermis. Moreover, using an experimental model
 
of LC migration induced by tumor necrosis factor (TNF)-
 
a
 
, we show that parasites transiently
impair the departure of LCs from the epidermis and their subsequent accumulation as den-
dritic cells in the draining lymph nodes. The inhibitory effect is mediated by soluble lipophilic
factors released by the parasites and not by host-derived antiinflammatory cytokines, such as
 
interleukin-10. We find that prostaglandin (PG)D
 
2
 
, but not the other major eicosanoids pro-
duced by the parasites, specifically impedes the TNF-
 
a
 
–triggered migration of LCs through
the adenylate cyclase–coupled PGD
 
2
 
 receptor (DP receptor). Moreover, the potent DP recep-
tor antagonist BW A868C restores LC migration in infected mice. Finally, in a model of con-
tact allergen-induced LC migration, we show that activation of the DP receptor not only in-
hibits LC emigration but also dramatically reduces the contact hypersensitivity responses after
challenge. Taken together, we propose that the inhibition of LC migration could represent an
additional stratagem for the schistosomes to escape the host immune system and that PGD
 
2
 
may play a key role in the control of cutaneous immune responses.
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Introduction
 
Dendritic cells (DCs)
 
1
 
 are professional APCs that initiate
primary immune responses in lymphoid tissues (1). Among
them, epidermal Langerhans cells (LCs) play a key role in
the establishment of cutaneous immunity. Under normal,
noninflammatory conditions, LCs reside in the epidermis
anchored to neighboring keratinocytes (KCs) via homo-
typic E-cadherin interactions (2). In this environment, they
display an immature phenotype characterized by high anti-
gen uptake and processing abilities and poor T cell stimula-
tory function. However, in response to stimulation occur-
ring during infection or topical application of allergens,
LCs activate, and a proportion of them migrates via afferent
lymphatics to regional LNs where they accumulate as im-
munostimulatory DCs (1, 3). Similarly, emigration of LCs
from the epidermis may be initiated via an antigen-inde-
pendent manner, for instance by skin irritants, ultraviolet
irradiation, or microbial CpG motifs (4, 5). During their
migration, LCs undergo a complex process of maturation,
becoming less effective in capturing and processing anti-
gens but more specialized in stimulating naive T lympho-
cytes. This latter property is partly mediated by an in-
creased expression of MHC class I and class II and
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Abbreviations used in this paper:
 
 AC, adenylate cyclase; CHS, contact hy-
persensitivity; CCR, CC chemokine receptor; DC, dendritic cell; DP re-
ceptor, PGD
 
2
 
 receptor; EIA, enzyme immunoassay; ES, excreted/secreted;
HETE, 5-hydroxyeicosatetranoic acid; KC, keratinocyte; KO, knockout;
LC, Langerhans cell; LT, leukotriene; RT, reverse transcription; SESP,
schistosomula ES products; SLN, skin-draining LN; WT, wild-type. 
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costimulatory molecules including intracellular adhesion
molecule (ICAM)-1 (CD54), CD40, B7-1 (CD80), and
B7-2 (CD86) (6).
The molecular mechanisms that govern LC migration
have been the purpose of extensive research in the past few
years. Accumulating evidence suggests that the synthesis of
inflammatory cytokines, particularly TNF-
 
a
 
 and IL-1
 
b
 
, is
one of the first events in the multistep cascade leading to
LC departure from the epidermis (7, 8). These cytokines
are respectively produced by KCs and LCs in response to
skin-penetrating pathogens or to contact allergens, and af-
fect the interactions between KCs and LCs by diminishing
the expression of E-cadherin (9) and by stimulating actin-
dependent movements of LCs (10). Other adhesion mole-
cules such as ICAM-1, very late antigen (VLA)-6 (CD49f),
CD40, and CD44 also play a role in the migratory proper-
ties of LCs. In addition, the importance of the seven trans-
membrane–spanning G protein–coupled receptor family
in driving LC motility has also been reported (11–14).
Among them, the CC chemokine receptor (CCR)7 is
sharply upregulated during LC maturation and is crucial to
attracting LCs into the LNs (11, 12). On the other hand,
LC emigration is associated with a rapid decrease in the ex-
pression of receptors for inflammatory chemokines such as
CCR1 (13).
Mechanisms controlling the emigration of epidermal
LCs after activation have been reported. In this phenome-
non, the antiinflammatory cytokine IL-1ra has been shown
to block the binding of IL-1
 
b
 
 to its receptor (15). Simi-
larly, IL-4 and IL-10 may act as negative regulators of LC
migration. Takayama et al. (16) recently showed that IL-4
interferes with the TNF-
 
a
 
–induced mobilization of LCs by
downregulating the expression of TNFR-II on LCs. In a
model of contact allergen-induced LC migration, Wang et
al. (17) suggested that IL-10 impedes LC emigration, at
least in part, by downregulating the synthesis of IL-1
 
b
 
 and
TNF-
 
a
 
 by epidermal cells. Although other components
may also be involved (18, 19), these studies suggest that LC
motility is tightly controlled by the homeostatic balance
between pro- and antiinflammatory cytokines produced
early in the skin, and that this balance quantitatively and
qualitatively affects the resulting adaptive immune response
(20). During cutaneous infections, skin-penetrating patho-
gens may directly or indirectly influence such events. For
instance, the intracellular parasite 
 
Leishmania major
 
 favors
the rapid production of inflammatory cytokines in the skin
and provokes LC migration to the skin-draining LNs
(SLNs; reference 21).
In this report, we have analyzed the effects of the hel-
minth parasite 
 
Schistosoma mansoni
 
, the causative agent of
schistosomiasis, on the activation state and migratory abili-
ties of LCs. Indeed recent demonstrations that schistosomes
interfere with some inflammatory pathways in host cells
(22–24) and that certain pathogens, particularly viruses and
intracellular parasites, can profoundly alter the functions of
DCs (25–29), prompted us to initiate this study. 
 
Schistosoma
mansoni
 
 has a complex migratory route within its vertebrate
host that is initiated by the penetration of the larvae
 
(termed cercariae) through the skin. In the cutaneous envi-
ronment, transformation of cercaria into schistosomulum is
accompanied by the release of a wide range of proteases
and fatty acid derivatives which facilitate parasite migration
through the skin (30). Additionally, parasite larvae closely
interact with cutaneous immunocompetent cells, while re-
maining in the skin for 3 to 4 d. The nature and immuno-
logical consequences of these interactions have not yet
been fully studied. Here, we show that, after murine infec-
tion, schistosomula activate LCs but, surprisingly, impede
their migration to the SLNs. This inhibitory effect, which
also occurs in a TNF-
 
a
 
–induced model of LC migration, is
mediated by excreted/secreted (ES) lipophilic factors pro-
duced by parasite larvae, particularly by PGD
 
2
 
. We specu-
late that schistosomes may utilize this stratagem to limit
and/or orientate the host immune response. We also pro-
pose a new function for PGD
 
2 
 
in skin homeostasis and in
the regulation of the cutaneous immune response.
 
Materials and Methods
 
Reagents and Abs.
 
All reagents were purchased from Sigma-
Aldrich unless otherwise notified. PGD
 
2
 
, PGE
 
2
 
, PGF
 
2
 
a
 
,
5-hydroxyeicosatetranoic acid (HETE), 15-HETE, leukotriene
(LT)B
 
4
 
, LTC
 
4
 
, and BW245C were from Cayman Chemical. BW
A868C was donated by Dr. S. Lister (Glaxo Wellcome, Green-
ford, UK). The anti-I-A
 
d
 
/I-E
 
d
 
 mAbs (clone M5/114, rat IgG2b)
and the anti-DEC-205 (NLDC-145, rat IgG2a) were provided
by Drs. A. Ager (National Institute for Medical Research, Lon-
don, UK) and D. Sacks (National Institutes of Health, Bethesda,
MD), respectively. The FITC-conjugated anti-CD80 (hamster
IgG), anti-CD86 (rat IgG2a), and biotin-conjugated anti-CD11c
(hamster IgG) mAbs were purchased from BD PharMingen. The
following were used as secondary Abs: biotin-conjugated anti–rat
and anti-FITC peroxidase-conjugated (Boehringer). The bio-
tinylated reagents were detected using ABC complex horseradish
peroxidase (HRP; Dako). The neutralizing anti–IL-10 mAb
(clone JES052A5, rat IgG1) was from R&D Systems and the iso-
type control mAb from Caltag Laboratories.
 
Cell Lines.
 
The LC line XS52 has been established from
mouse epidermis and presents the phenotypic and functional fea-
tures of LC (31). XS52 was cultured in RPMI containing 10%
(vol/vol) heat-inactivated FCS in the presence of 2 ng/ml GM-
CSF (Biosource International) and 10% (vol/vol) NS47 fibroblast
supernatant as described (32). Mouse Pam212 KCs were cultured
in Eagle’s MEM complemented with 10% FCS and 0.05 mM
CaCl
 
2
 
 (31).
 
Mice, Parasites and Infection Protocols.
 
Young adult wild-type
(WT) and IL-10–deficient (knockout [KO]) C57BL/6 mice (6-
to 8-wk old) were purchased from Iffa-Credo. The 
 
S. mansoni
 
(Puerto Rican strain) life cycle was maintained in 
 
Biomphalaria
glabrata
 
 snails as the intermediate host and the hamster 
 
Mesocricetus
auratus
 
 as the definitive host. Skin schistosomula and schistoso-
mula ES products (SESP; the supernatant of a 4-h culture con-
taining 10
 
3
 
 parasites/ml) were prepared as described (23, 24). The
methanol/chloroform-extracted fraction from the SESP (termed
the lipophilic fraction) was obtained by a modified Folch extrac-
tion protocol (24). The organic phase was dried under a stream of
nitrogen and resuspended in DMSO (for biological studies) or
methanol (for HPLC analysis) (50 
 
m
 
l/50 ml parasite culture). For
 
S. mansoni
 
 infection, mice were anesthetized with pentobarbital 
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(30 mg/kg; Sanofi) and exposed to 250 cercariae by immersion of
the ears for 25 min.
 
Identification and Quantification of Eicosanoids.
 
Eicosanoids re-
covered from the schistosomula culture medium were extracted
as described above and analyzed by HPLC on a 3.9 
 
3
 
 150 mm
Novapack C-18 reverse phase column (Waters). Elution was car-
ried out at a rate of 0.5 ml/min with acetonitrile/water (40:60
vol/vol) plus 0.01% (vol/vol) trifluoroacetic acid. Peak elution
was monitored at 195 nm for PGs, 230 nm for conjugated dienes,
and 270 nm for LTs. Identification and quantification of various
HPLC peaks were performed by injecting known quantities of
eicosanoid standards. Enzyme immunoassay (EIA) was also used
to quantify PGF
 
2
 
a
 
, PGE
 
2
 
, PGD
 
2
 
, LTB
 
4
 
, and LTC
 
4 
 
directly from
the parasite culture supernatant with kits provided by Cayman.
Results in Table II represent the concentration of individual
eicosanoid detected per ml of culture (10
 
3
 
 parasites/ml).
 
Cytokine and Ab Administration.
 
Recombinant murine TNF-
 
a
 
(specific activity 
 
$
 
 5 
 
3
 
 10
 
7
 
 U/mg) (R&D Systems) was reconsti-
tuted in sterile PBS containing 0.1% (wt/vol) BSA as a carrier
protein. Mice were intradermally injected with 50 ng TNF-
 
a
 
 (30
 
m
 
l) into both ear pinnae with 27 3/4-gauge stainless steel needles.
Epidermal sheets were analyzed 1 h after injection, a time previ-
ously shown to be optimal for TNF-
 
a
 
–induced LC emigration
(7). Treatment of mice with Abs was as follows: 1 h before infec-
tion, C57BL/6 mice were injected intradermally with 40 
 
m
 
g of
neutralizing anti–IL-10 or isotype-matched control mAb diluted
in sterile PBS (final volume: 30 
 
m
 
l).
 
Preparation and Analysis of Epidermal Sheets.
 
The epidermis
was separated from the dermis by means of ammoniumthiocya-
nate as described previously (33). Epidermal sheets were fixed in
paraformaldehyde (PFA; 2% in PBS) for 10 min at room temper-
ature, and washed three times with PBS. For immunohistochem-
ical staining, sheets were placed for 15 min in 3% H
 
2
 
O
 
2
 
 to inhibit
endogenous peroxidase, washed three times with PBS, and incu-
bated for 30 min with PBS plus 1% (wt/vol) blocking reagent
(Boehringer). Epidermal sheets were then incubated with primary
Abs for 90 min and washed in PBS before adding either bio-
tinylated conjugated goat anti–rat Ig or peroxidase-conjugated
anti-FITC for an additional 30 min. In the final step, sheets were
developed with 3-amino 9-ethyl carbazol, washed three times in
PBS, and mounted onto glass slides in Immumount (Shandon)
for immunohistochemical analysis. LCs were enumerated by
counting MHC class II–positive cells. Epidermal sheets were pre-
pared from each experimental group and for each sheet 10 ran-
dom fields were examined. Cell frequency was converted to LC/
mm
 
2
 
 and results were expressed as mean 
 
6 
 
SD. The statistical
significance of differences between experimental groups was cal-
culated using the Student’s 
 
t
 
 test.
 
Skin Explant Assay.
 
After treatment, ears were rinsed in 70%
ethanol and split into dorsal and ventral halves with forceps (34).
Four sheets were floated, dermal side down, on 4 ml RPMI sup-
plemented with 25 mM Hepes, 10% FCS, and gentamycin (50
 
m
 
g/ml). After 24 h incubation at 37
 
8
 
C in a 5% CO
 
2
 
 incubator,
epidermal sheets were prepared and LCs were enumerated as de-
scribed above.
 
Immunochemical Analysis of SLNs.
 
SLNs were removed 18 h
after TNF-
 
a
 
 treatment and fixed in a formaldehyde-free zinc fix-
ative (ImmunoHistoFix; Interstiles sprl) for 7 d at 4
 
8
 
C. After de-
hydration in graded alcohol baths, embedding was performed by
three successive immersions in ImmunoHistoWax (Interstiles
sprl) at 37°C. Sections of 5 
 
m
 
m thickness were dewaxed in ace-
tone for 5 min and immunostained with anti-CD11c Ab as de-
scribed above. For immunohistochemical analysis, sections were
counterstained with hematoxylin and mounted in Immumount.
 
Induction and Elicitation of Contact Hypersensitivity Responses.
 
Mice were sensitized by painting 10 
 
m
 
l of a 0.5% solution of FITC
prepared in acetone/dibutylphtalate (1:1, vol/vol; vehicle) on the
total surface of the left ear. 30 
 
m
 
l of BW245 (100 nM) or DMSO
(as a control) was injected intradermally 15 min before and 5 h af-
ter sensitization. Contact hypersensitivity (CHS) was elicited 5 d
after the sensitization by painting the dorsal and ventral surface of
the right ear with 10 
 
m
 
l of 0.5% FITC (35). Ear thickness was
 
Table I.
 
Sequences of Primers Used for PCR Amplification of cDNA, Product Sizes, and PCR Cycle Numbers
 
Gene Primer Sequence
Size
(bp) Cycle
 
b
 
-actin 5
 
9
 
5
 
9
 
-GTCGGGCGCCCCAGGCACCA
 
539 28
3
 
9
 
5
 
9
 
-CTCCTTAATGTCACGCACGATTTC
 
TNF-
 
a
 
5
 
9
 
5
 
9
 
-AACCACCAAGTGGAGGAGCAGC
 
312 36
3
 
9
 
5
 
9
 
-TGACCTCAGCGCTGAGTTGGTCC
 
IL-1
 
b
 
59 59-TGAAGGGCTGCTTCCAAACCTTTGACC 322 36
39 59-TGTCCATTGAGGTGGAGAGCTTTCAGC
IL-1ra 59 59-CCTGCAAGATGCAAGCCTTCAGG 353 35
39 59-CAGCCTCTAGTGTTGTGCAGAGG
IL-4 59 59-GAATGTACCAGGAGCCATATC 384 38
39 59-CTCAGTACTACGAGTAATCCA
TNFR-II 59 59-GTAGGCCTTGAGCAGCAGCACCT 312 35
39 59-GTGTCTCTGTAGTCTCACACGG
IL-10 59 59-TCCTTAATGCAGGACTTTAAGGGTTAC 246 38
39 59-GACACCTTGGTCTTGGAGCTTATTAAA
DP receptor 59 59-GAAGTTCGTGCAGTACTGTCCAG 435 35
39 59-TCCACTATGGAAATCACAGACAG1138 PGD2 and Langerhans Cell Migration
measured using an engineers’ micrometer (Mitutoyo) 24 h after
challenge. Results are expressed as ear swelling, which was calcu-
lated by subtracting the thickness of the ear before the challenge
from the thickness of the ear after the challenge. In experiments
where elicitations were not required, mice were killed 18 h (for
the determination of epidermal LC density) or 24 h after sensitiza-
tion. To determinate the number of migrating FITC-positive
DCs in the SLNs, single cell suspensions were prepared from au-
ricular LNs and DCs were enriched by centrifugation on a 14.5%
(wt/vol) metrizamide gradient. DCs were then stained with the
biotin-conjugated anti-CD11c mAb followed by phycoerythrin-
streptavidin. The percentage of CD11c 1FITC1 LN cells was de-
termined on a FACSCalibur™ flow cytometer (Becton Dickin-
son). Data were analyzed using CELLQuest™ software.
mRNA Extraction and Reverse Transcription PCR Amplifica-
tion. Ears from mice were excised, the epidermis were separated
from the dermis, and total RNA was isolated using TRIzol reagent
(Life Technologies). RNA from resting XS52 and Pam212 cells
were isolated as described above. cDNA was synthesized from 1
mg of total RNA with random hexamer primers and Superscript
reverse transcriptase (Life Technologies) using standard procedures.
PCR amplifications were performed with the primer pairs indi-
cated in Table I. Amplified products were subjected to 1% agarose
gel electrophoresis and visualized by ethidium bromide staining.
Results
S. mansoni Induces LC Activation In Vivo. The distribu-
tion of epidermal LCs was visualized by immunohis-
tochemical staining with anti-MHC class II molecule Abs
in noninfected or S. mansoni–infected skins (Fig. 1, A and
B). In a kinetic study (1 to 120 h), the morphology of epi-
dermal LCs dramatically differed in infected sheets com-
pared with controls at all time points examined. In infected
skins, LCs markedly increased in size and exhibited a more
dendritic morphology with typical interdigiting cellular
processes. Moreover, the MHC class II staining on LCs
from infected epidermis was more intense. Immunolabel-
ing with the LC-specific Ab NLDC-145 confirmed the ac-
tivated phenotype of LCs in infected skins (not shown).
We next analyzed other surface markers known to be ex-
pressed by mature LCs. Although we could barely detect
CD86-positive cells in control epidermis (Fig. 1 C), the ex-
pression of CD86 on LCs was strongly upregulated in in-
fected skins, 12 h (Fig. 1 D) to 120 h (not shown) after par-
asite penetration. Interestingly, most of the CD86-positive
cells were located in the vicinity of the parasite or around
Figure 1. Immunohistochemical staining of murine epidermal sheets after transcutaneous infection by S. mansoni. Epidermal sheets were prepared either
from noninfected or from S. mansoni–infected mice and LCs were stained for MHC class II (A and B) or for CD86 (C and D). The arrow indicates the
“ghost” of parasite. The isotype control mAb did not reveal any reactivity (not shown). Original magnification: 3400.1139 Angeli et al.
its “ghost.” In contrast, we were unable to detect any
CD80-positive cells either in noninfected or infected skins
whatever time after infection (not shown). Taken together,
our data suggest that, early after S. mansoni infection, LCs
display clear signs of activation, exhibiting a more dendritic
appearance and expressing higher amounts of MHC class II
and CD86 molecules.
S. mansoni Induces Retention of Activated LCs in the Epider-
mis In Vivo and Ex Vivo. As after activation, LCs nor-
mally migrate from the epidermal site of antigen capture to
the SLNs, we attempted to study the migratory behavior of
LCs after S. mansoni penetration. To this end, the fre-
quency of MHC class II–positive cells was determined in
the epidermis at different times after infection (1 to 120 h).
As shown in Fig. 2 A, the density of MHC class II–positive
epidermal cells in naive and noninfected mice ranged be-
tween 450 to 470 LCs/mm2. Surprisingly, in comparison
to control epidermis, the number of LCs/mm2 remaining
in the epidermis was not reduced 1 to 120 h after S. man-
soni infection. To confirm this data, we used a complemen-
tary approach based on the spontaneous migration of LCs
from skin explants cultured in vitro for 24 h (34; Fig. 2 B).
In noninfected mice, compared with a freshly isolated epi-
dermis, the number of LC/mm2 remaining in the epider-
mis after 24 h culture dramatically decreased to 188 6 22
(vs. 452 6 32, 58% reduction). In contrast, in infected ani-
mals, the density of LCs remained constant 6 to 48 h after
infection and decreased significantly to 225 6 11 (50% re-
duction) 120 h after infection, a period that coincides with
the departure of the parasites from the skin. Together, both
in vivo and ex vivo approaches suggest that parasite infec-
tion causes the activation of epidermal LCs but prevents
their migration from the epidermis.
S. mansoni Inhibits the TNF-a–induced Migration of LCs.
We next investigated whether S. mansoni infection could
alter LC migration in a system known to promote a strong
LC departure to the SLNs (7). For this purpose, mice were
injected into ear pinnae with TNF-a and the capacity of
LCs to emigrate from the skin was then assessed 1 h after
injection. As shown in Fig. 3 A, in noninfected mice,
TNF-a caused z54% reduction in LC frequency com-
pared with control mice (carrier). By contrast, infection by
S. mansoni inhibits the TNF-a–induced LC migration 6
and 24 h after infection. Interestingly, the migratory ability
of LCs was restored in mice infected 120 h before TNF-a
treatment. Taken together, these results show that schisto-
somula transiently interfere with TNF-a to inhibit LC mi-
gration from the epidermis to the SLNs. To further con-
firm this, we visualized the accumulation of DCs in the
SLNs isolated from TNF-a–treated mice previously in-
fected (24 h before TNF-a treatment) or not with S. man-
soni. As observed in Fig. 3 B, in noninfected mice, TNF-a
administration resulted in increased number of CD11c-
positive cells in the T cell areas of the SLNs whereas few
CD11c-positive cells were detected in the SLNs from
TNF-a–treated S. mansoni–infected mice.
IL-10 Is Not Sufficient to Inhibit LC Migration in S. manso-
ni–infected Mice. To determine the mechanism by which
S. mansoni inhibits LC migration, we first investigated by
reverse transcription (RT)-PCR the presence of mRNAs
for cytokines known to control LC mobility at various
times after infection (1 to 120 h). As shown in Fig. 4 A,
compared with noninfected mice (0 h), we observed a
rapid and sustained increase in TNF-a and IL-1b mRNA
levels in the epidermis of infected mice suggesting that the
signals required for LC departure may be present. We then
tested the hypothesis that the observed inhibitory effect
could be associated with the expression of antiinflammatory
cytokines. Interestingly, we detected a marked up-regula-
tion of IL-10 mRNA, particularly between 6 and 24 h after
infection. In contrast, we found that infection did not sig-
nificantly affect the basal level of IL-1ra mRNA expression.
In infected mice, the level of IL-4 mRNA increased pro-
gressively between 1 to 120 h after infection and this
change was accompanied by a gradual decrease in mRNA
Figure 2. Effect of S. mansoni infection on the migration of epidermal
LCs in vivo (A) and ex vivo (B). (A) Epidermal sheets were prepared at
different times after the infection (1 to 120 h) and the number of LC/mm2
was determined after anti-MHC class II staining. Controls included epi-
dermal sheets from naive mice and from mice exposed to water without
parasites (Non-infected). Results are expressed as means 6 SD and are
representative of four independent experiments (n 5 7). (B) Skin explants
were obtained from ears of noninfected or S. mansoni–infected mice (6,
24, 48, and 120 h). The number of LC/mm2 was determined in the epi-
dermis from the explants after 24 h of culture and compared with the epi-
dermis from fresh skin (naive). Results are expressed as means 6 SD and
are representative of three independent experiments (n 5 4). Significant
differences are designated by * (P , 0.001).1140 PGD2 and Langerhans Cell Migration
levels of TNFR-II, but not by a total disappearance of the
signal, in infected mice. Altogether, based on recent find-
ings (17), our data suggest that IL-10 might be involved in
the control of LC migration after S. mansoni infection. To
test this hypothesis, IL-10 KO mice were infected and the
density of LCs on epidermal sheets was assessed by immu-
nohistochemistry 24 h after infection. As shown in Fig. 4
B, the number of LC/mm2 was identical in the epidermis
of noninfected and infected IL-10–deficient mice, whereas
TNF-a dramatically depleted the population of LCs by
.60%. It is worth mentioning that in IL-10 KO mice, LCs
exhibited an activated phenotype after parasite infection.
Similar results were obtained in WT mice by using anti–
IL-10 neutralizing mAbs injected intradermally before in-
fection (Fig. 4 B). These data indicate that the inhibition of
LC migration in S. mansoni–infected skin probably involve
other factors than antiinflammatory host-derived cytokines.
ES Lipophilic Substances from Schistosomula Inhibit the
TNF-a–induced LC Migration In Vivo. We then investi-
gated the possibility that factors released by parasites them-
selves may directly affect LC migration. To this end, SESP
were intradermally injected into the ear pinnae and the
density of LCs remaining in the epidermis was determined
1 h after TNF-a injection. As seen in Fig. 5 A, SESP had a
strong inhibitory effect on the TNF-a–induced LC mobil-
ity. We have previously demonstrated that the SESP con-
tain bioactive lipophilic compounds able to activate host
cells (24). We therefore tested the effect of the lipophilic
Figure 3. Effect of S. mansoni infection on the TNF-a–induced LC migration in vivo. (A) 6, 24, and 120 h after infection, mice (four mice/time
point) were intradermally injected with 30 ml of PBS/BSA (carrier) containing or not containing 50 ng TNF-a into both ear pinnae. Ears were removed
1 h later, epidermal sheets were prepared, and the number of LC/mm2 was determined by immunohistochemistry. In TNF-a–treated S. mansoni-
infected mice, we noted that LCs remained interdigitated among surrounding KCs and still expressed E-cadherin (not shown). The experiment shown is
representative of five experiments (n 5 8) and values are means 6 SD. (B) Detection of CD11c-expressing cells in SLNs from TNF-a–treated mice pre-
viously (24 h), or not, infected with S. mansoni (original magnification: 3200).1141 Angeli et al.
fraction from the SESP, obtained by a modified Folch ex-
traction protocol, on the TNF-a–induced LC departure.
Compared with the control (DMSO), we found that the li-
pophilic fraction dose dependently abrogates the departure
of LCs from the epidermis (Fig. 5 B). Previous studies re-
vealed that parasite larvae secrete various arachidonic acid–
derived eicosanoids and that PGD2, PGE2, 5-HETE, 15-
HETE, LTB4, and LTC4 are the major compounds (30,
36). Using different chromatographic systems, such as thin-
layer chromatography (not shown) and HPLC, we con-
firmed these data except for LTs (detected in low amounts
in the lipophilic fraction) and PGF2a (present in a detectable
level) (Fig. 6). As represented in Table II, quantification by
HPLC and/or EIA revealed that, in our culture conditions,
the parasite culture supernatant contains micromolar con-
centrations of PGF2a, PGE2, PGD2, 5-HETE, 15-HETE,
and nanomolar concentrations of LTB4 and LTC4.
PGD2 Specifically Inhibits the TNF-a–induced LC Mi-
gration through a cAMP-dependent Pathway. We therefore
tested each of these molecules in our in vivo system of
TNF-a–induced LC departure. As shown in Fig. 7 A, in-
tradermal administration of increasing amounts of PGD2 sig-
nificantly inhibits LC migration in a dose-dependent man-
ner. In contrast, PGF2a, PGE2, 5-HETE, and 15-HETE
did not prevent the mobility of LCs after TNF-a treatment,
although at 100 nM, 5- and 15-HETE partially increased
the LC density compared with animals that received
DMSO alone. Similarly, LTB4 and LTC4 had no effect (not
shown). Although we do not exclude the possibility that
other lipophilic compounds may also be involved, this
strongly suggests that schistosomula may exert its inhibitory
effect on LC mobility through the production of PGD2. To
confirm this, we used a synthetic analogue of PGD2 that is
Figure 4. (A) RT-PCR anal-
ysis of mRNAs specific for pro-
and antiinflammatory cytokines
in the epidermis of S. mansoni–
infected mice. Epidermal sheets
were prepared from noninfected
(0 h) or infected (1, 6, 24, and
120 h) mice, total RNA ex-
tracted, and RT-PCR was car-
ried out using the primers shown
in Table I. Representative results
of three independent experi-
ments are shown. (B) Role of
IL-10 in the inhibition of LC
migration. IL-10 KO or WT
mice were infected (or not) and
24 h after infection, epidermal
sheets were prepared and the
number of LCs/mm2 determined
by immunohistochemistry. Be-
fore infection, WT mice were
treated with neutralizing anti–
IL-10 or isotype-matched mAbs
(IgG1). As a positive control,
TNF-a was intradermally in-
jected 1 h before the analysis.
Significant differences are desig-
nated by * (P , 0.001).
Figure 5. Effect of SESP on the TNF-a–induced LC migration in
vivo. (A) The supernatant of a 4-h culture of schistosomula (SESP) or
(B) increasing amounts of the lipophilic fraction from the SESP (diluted
in DMSO) were intradermally injected to mice. After 20 min, mice
were treated with 50 ng of TNF-a and the epidermal sheets were ana-
lyzed 1 h after for the determination of LC density. These data are repre-
sentative of three experiments (n 5 4). Significant differences are desig-
nated by * (P , 0.001).1142 PGD2 and Langerhans Cell Migration
highly specific for the PGD2 receptor (DP receptor; refer-
ence 37). As seen in Fig. 7 B, compared with DMSO-
treated animals, BW245C (10 nM) also abrogates the migra-
tion of LCs induced by TNF-a. As PGD2, and particularly
BW245C, are known to increase the level of intracellular
cAMP via its specific binding to the adenylate cyclase (AC)-
coupled DP receptor (37), we hypothesized that cAMP may
be the major signaling pathway involved in LC blockade.
To this end, we tested the effect of the AC activator forsko-
lin. As represented in Fig. 7 C, we found that forskolin (10
mM) abrogates the TNF-a–induced emigration of LCs.
Taken together, our data suggest that the retention of LCs
in the epidermis is likely mediated by a cAMP-dependent
mechanism specifically triggered by PGD2.
The DP Receptor Mediates the Inhibition of LC Migration In-
duced by Schistosoma. We next verified by RT-PCR that
the DP receptor is expressed on murine epidermal cells.
For this purpose, as purification of freshly isolated LCs and
KCs from mouse epidermis is extremely difficult to realize,
we used the LC (XS52) and KC (Pam212) lines. As de-
picted in Fig. 8 A, we detected mRNA for the DP recep-
tor in total epidermal cells, in the LC and, to a lesser
extent, in the KC line. To demonstrate that the parasite-
induced inhibitory effect on LC migration is due to the
specific binding of PGD2 to the DP receptor, we treated
mice with the highly specific DP receptor antagonist BW
A868C 15 min before infection. 6 h later, the LC fre-
quency was established in DMSO- and in BW A686C-
treated animals. As shown in Fig. 8 B, BW A868C dose
dependently restores the ability of LCs to leave the epider-
mis in infected mice. Altogether, these results show that
targeting of PGD2 to the KC- and/or to the LC-expressed
DP receptor is responsible for the blockade of LC emigra-
tion from the epidermis during infection by Schistosoma.
BW245C Inhibits CHS Responses Elicited by FITC. To
confirm our finding, we tested the effect of the DP recep-
tor agonist BW245C in a model of contact sensitization in-
duced by the hapten FITC (35). Compared with unsensi-
tized mice, the number of LCs was reduced in the
epidermis of sensitized mice 18 h after FITC painting (Fig.
9 A). In contrast, we found that LC migration is signifi-
cantly impaired in BW245C-treated mice compared with
sensitized control mice (DMSO/FITC). As assessed by
flow cytometry, this defect in LC departure was associated
with a dramatic reduction of the number of CD11c, FITC
double-positive cells in the SLNs 24 h after sensitization
(Fig. 9 B). Finally, to investigate whether the activation of
the DP receptor during the sensitization phase results in an
altered development of LC-dependent immune response,
we measured the CHS response 5 d after FITC challenge.
As expressed as ear swelling, BW245C-treated mice devel-
oped a profoundly reduced CHS responses (80% inhibi-
tion) compared with controls.
Discussion
Migration of LCs from the epidermis to the SLNs is a
tightly regulated multistep process requiring inflammatory
cytokines, chemokines, and adhesion molecules. However,
very few studies have been devoted to investigate the mo-
lecular mechanisms which negatively regulate LC depar-
ture from the skin, especially during infections. In this re-
Figure 6. HPLC analysis of S. mansoni schistosomula eicosanoid pro-
duction. 1 ml of the lipophilic fraction was injected, fractions were col-
lected every 30 s, and monitored using a densitometer (wavelength: 195,
230, and 270 nm). The elution position of external standards are indicated.
Note that the scales of the arbitrary values are different in each panel.
Table II. Schistosomula Eicosanoid Production as Determined by 
HPLC and/or EIA
Eicosanoid
Retention
time Wavelength Concentration Concentration*
min nm pg/ml mm pg/ml mm
PGF2a 4.32 195 2,359 6.53 1,841 5.09
PGE2 5.68 195 2,273 6.43 2,589 7.32
PGD2 6.57 195 691 1.96 752 2.13
15-HETE 98 230 263 0.82 nd nd
5-HETE 150 230 218 0.68 nd nd
LTB4 26 270 nd nd 18 0.05
LTC4 66 270 nd nd 14 0.04
Shown is one representative experiment out of four. nd, not
determined.
*Concentration determined by EIA.1143 Angeli et al.
port, we show for the first time that PGD2 directly inhibits
the migration of LCs from the epidermis. This finding sug-
gests a novel and unexpected function for this PG member
in the control of LC homeostasis in the skin.
During cutaneous infections, skin-penetrating pathogens
(in)directly activate LCs to migrate to the SLNs and may
eventually use them to invade the hosts (21, 38). During
schistosomiasis, little is known about the immunological
consequences of the interactions between schistosomes and
cutaneous cells. Sato et al. suggested that resident LCs may
participate in the initiation of the primary immune re-
sponse in S. mansoni–infected guinea pigs, but the major
APCs involved are rather newly recruited blood-born skin
LCs/DCs (39, 40). In another study, Riengrojpitak et al.
hypothesized that infiltrating dermal APCs are important in
the T cell priming in the SLNs (41). In this report, we in-
vestigated the possibility that S. mansoni may affect LC
functions in vivo during murine infection. After checking
that LCs did not undergo apoptosis after parasite penetra-
tion (data not shown), we showed that LCs exhibited evi-
dent signs of activation characterized by modifications of
both LC morphology and phenotype, particularly for cells
in the vicinity of the parasites or of their “ghosts”. Further-
more, we assessed the frequency of LCs in epidermal sheets
from freshly isolated or from explanted infected skins. In
both cases, we found that LCs are retained in the epidermis
at all time points after infection (except at 120 h for the ex-
plants). Moreover, immunohistochemical analysis revealed
no detectable DC accumulation in the SLNs from infected
mice (1 to 10 d after infection, not shown). These results
do not support those of Sato et al. who reported a signifi-
cant LC depletion 12 h after infection in the guinea pig
model (39). This may be attributed to differences in the an-
imal models, in the schistosome species, or in the protocol
of infection used. Interestingly enough, our observation
was confirmed in a model of LC migration provoked by
TNF-a. Indeed, we show that parasites transiently inhibit
the TNF-a–induced release of LCs from the epidermis and
the subsequent accumulation of DCs in the SLNs. Al-
though not yet understood, this phenomenon has recently
been described as a possible mechanism that could prevent
and/or control the activation of immune responses against
skin tumors (42) or retroviruses (43). Consequently, thera-
peutics able to antagonize the inhibitory effects which
block LC migration (caused by abnormal cells or by patho-
gens) would be of great value. Whether or not Schistosoma
used this stratagem to control and/or to orientate the cuta-
neous immune response is an open question which de-
serves further investigation. Indeed, despite the herein de-
scribed inhibitory effect, we cannot exclude the possibility
that some antigen-bearing LCs may migrate to the SLNs to
initiate the response. Similarly, other cutaneous APCs (der-
Figure 7. Effect of (A) the major schistosomula
ES eicosanoids and (B) of the PGD2 analogue
BW245C and the cAMP-elevating agent forskolin
on the TNF-a–induced LC migration in vivo. (B)
Mice received increasing concentrations of PGF2a,
PGE2, PGD2, 15-HETE, 5-HETE, or vehicle
alone (DMSO), or (B) they received BW245C (10
nM), forskolin (10 mM), or DMSO. After 20 min,
mice were treated with 50 ng of TNF-a and epi-
dermal sheets were prepared 1 h later. The number
of LC/mm2 was determined by immunohis-
tochemistry. This data is representative of three ex-
periments (n 5 4). Significant differences are desig-
nated by * (P , 0.001).
Figure 8. (A) Expression of mRNA for the DP receptor in
total epidermal cells and in the LC (XS52) and KC (Pam212)
lines as assessed by RT-PCR. (B) Effect of the DP receptor
antagonist BW A868C on LC emigration after infection with
S. mansoni. 15 min before the infection, mice were injected
intradermally with increasing amounts of BW A868C. 6 h
later, epidermis were stained using anti-MHC class II Abs.
This data is representative of three experiments (n 5 4). Sig-
nificant differences are designated by * (P , 0.001).1144 PGD2 and Langerhans Cell Migration
mal DCs; reference 39) or SLN resident APCs (41) may
also be important in initiating the immune response during
schistosomiasis. Moreover, by transiently affecting the mi-
gration of LCs, Schistosoma may not only delay the induc-
tion of the immune response but also, by “exhausting”
LCs, favor the priming of type 2 and nonpolarized T cells,
as recently suggested by Langenkamp et al. (44).
We next explored the mechanisms that lead to the reten-
tion of LCs in the epidermis and attempted to identify the
responsible factor(s). We first assessed by RT-PCR the ex-
pression of cytokines known to be involved in LC migra-
tion. We hypothesized that the antiinflammatory cytokine
IL-10 may be implicated. Indeed, and in accordance with a
recent report (45), we showed that IL-10–specific mRNA
is strongly increased in S. mansoni–infected skin. Despite
this, using IL-10 KO mice or WT mice treated with neu-
tralizing anti–IL-10 Abs, we still observed the inhibition of
LC migration in infected epidermis. Similarly, RT-PCR
analysis suggest that the chemokine receptors CCR-1 and
CCR-7 do not appear to be implicated in the herein de-
scribed inhibitory effects (not shown). We then proceeded
to the hypothesis that factors released by parasites while
penetrating the skin may inhibit the TNF-a–induced sig-
nals involved in LC migration. We found that injection of
lipophilic factors from the SESP mimicked the inhibitory
effects observed during infection. We then tested the ef-
fects of the major cyclooxygenase and lipoxygenase prod-
ucts found in the SESP on the TNF-a–triggered migration
of LC. Among them, we found that PGD2 specifically in-
duces the retention of LCs in the skin after TNF-a treat-
ment. We propose that PGD2 activates LCs by interacting
with the AC-coupled DP receptor and that the resulting
signaling pathway interferes with the TNF-a–induced sig-
nals implicated in LC departure. This later assumption is
important as PGD2, as well as its metabolite 15d-PGJ2, can
also activate the peroxisome proliferative-activated recep-
tors, a family of nuclear receptors recently shown to inhibit
the chemoattractant-induced migration of various cells (46,
47). In the same manner, a novel receptor for PGD2 has re-
cently been described (48). Interestingly, this seven trans-
membrane G protein–coupled receptor (termed CRTH2)
is expressed on human T helper type 2 lymphocytes, eo-
sinophils, and basophils and is involved in their recruitment
to allergic inflammatory sites. We eliminate the possibility
that CRTH2 may be involved in the inhibition of LC mi-
gration as (a) we did not find mRNA CRTH2 expression
in the LC line XS52 (not shown), (b) BW245C is a poor
agonist for CRTH2 (48), and (c) CRTH2 is not coupled
to an AC system but, on the contrary, induces Ca2 1 mobi-
lization in activated cells. Therefore, the dual action of
PGD2 in either favoring or inhibiting cell migration is
probably due to a selective expression of CRTH2 or DP
receptor on target cells.
To our knowledge, PGD2 is the first molecule described
to impair LC migration in vivo by directly affecting LC
motility. Indeed, although other mechanisms may also take
place (18, 19), compounds known to block LC migration
act rather by diminishing the synthesis or the release of in-
flammatory cytokines (49–51) or by interfering with their
activities (52). For instance, in UVB- or enterotoxin-
treated mice, agents that block protein kinase C or G pro-
tein–associated kinases inhibit LC departure in part by pre-
venting the release of TNF-a or IL-1a in the epidermis
(50, 53, 54). In this report, we show that, in a TNF-a–
induced model of LC depletion, activation of the cAMP-
mediated pathway inhibits LC departure from the skin. In
this model, the exact mechanisms by which cAMP inhibits
the TNF-a–induced migratory abilities of LCs are not elu-
cidated but probably involve remodelling of the actin net-
work and the reinforcement of contact between LCs and
KCs. In these processes, different protein targets for cAMP
may be involved including the small GTP-binding proteins
rho, tyrosine kinases, or adhesion molecules (55). For in-
stance, the sustained E-cadherin expression on LCs in S.
mansoni–infected skins (even after TNF-a treatment; not
shown), may be one of these.
In addition to its role in the development and/or the
modulation of acute and chronic inflammation (56–58),
PGD2 has multiple effects on the immune system. It en-
hances the release of mediators by eosinophils and mast
Figure 9. Effect of the PGD2 analogue BW245C on the FITC-
induced migration of LCs and on CHS responses. Mice were injected
intradermally into ear pinnae with BW245C (100 nM) 15 min before
and 5 h after FITC topical application. (A) Epidermal LC density was an-
alyzed 18 h after FITC painting and (B) the number of CD11c1FITC1
cells present in the SLNs determined 24 h after FITC application. (C) 5 d
after sensitization, mice were challenged and 24 h later, ear thickness was
measured. Results are expressed as means 6 SD and are representative of
three independent experiments (n 5 7). Significant differences are desig-
nated by * (P , 0.001) for A and C and (P , 0.05) for B.1145 Angeli et al.
cells, reduces the production of superoxide in neutrophils,
and suppresses T cell mitogenesis (59, 60). Here, we de-
scribe a novel function for PGD2 in that, during immune/
inflammatory reactions, it may also control the migration of
APCs from the site of antigen capture to the LNs. In the
skin, PGD2 is among the major arachidonic acid metabo-
lites produced (together with PGE2 and HETEs), particu-
larly in the epidermis. Besides its role in KC proliferation
and differentiation and in inflammatory responses (61), we
propose that PGD2 may also act as an upstream component
in a cascade of events that regulate the emigration of LCs
from the skin, by a feedback mechanism. This hypothesis is
supported by data showing that increased production of
PGD2 is observed in the skin after UVB irradiation or anti-
gen challenge (62). During infections, host- as well as
pathogen-derived PGD2 synthase (the enzyme which trans-
forms PGH2 to PGD2) may therefore play a key role in the
maintenance of LC homeostasis in the skin. In our model,
we have recently identified the parasite enzyme responsible
for PGD2 synthesis in schistosomes. This PGD2 synthase is
massively excreted by parasites while penetrating through
the skin (unpublished data). Consequently, in addition to
the endogenously produced PGD2, it is likely that Schisto-
soma may exploit the lipid metabolism of the host to con-
vert fatty acid precursors into PGD2.
Our findings may have important consequences in the
improvement of therapeutic treatments which aim to con-
trol skin diseases. Indeed, using a CHS model system, we
have confirmed the potent ability of DP receptor agonists
to inhibit LC migration out of the skin and to impair DC
accumulation in the LNs. Furthermore, this defect in LC
migration after hapten sensitization was associated with de-
fective CHS responses after challenge. At present, we are
testing the efficiency of PGD2 analogues (agonists and/or
antagonists of the DP receptor) as well as modulators of the
PGD2 synthase activity in diseases where reduction of im-
mune cutaneous response is sought, such as eczematous and
atopic dermatitis or, conversely, in diseases where stimula-
tion of LC migration would be beneficial, such as in certain
skin cancers (carcinomas) and infectious pathologies.
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